Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel Purchases 1,800 Shares of Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel acquired 1,800 shares of the company’s stock in a transaction that occurred on Tuesday, January 7th. The shares were acquired at an average cost of $13.75 per share, for a total transaction of $24,750.00. Following the purchase, the chief executive officer now directly owns 5,550,002 shares of the company’s stock, valued at $76,312,527.50. This represents a 0.03 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link.

Snehal Patel also recently made the following trade(s):

• On Thursday, January 2nd, Snehal Patel purchased 2,000 shares of Greenwich LifeSciences stock. The stock was bought at an average cost of $11.97 per share, for a total transaction of $23,940.00.
• On Monday, December 30th, Snehal Patel bought 3,200 shares of Greenwich LifeSciences stock. The stock was bought at an average cost of $11.12 per share, for a total transaction of $35,584.00.

Greenwich LifeSciences Price Performance

Shares of Greenwich LifeSciences stock opened at $13.35 on Thursday. Greenwich LifeSciences, Inc. has a 1 year low of $8.00 and a 1 year high of $21.44. The firm’s 50-day moving average is $13.15 and its 200 day moving average is $14.13. The stock has a market cap of $175.49 million, a price-to-earnings ratio of -16.69 and a beta of 1.66.

Institutional Investors Weigh In On Greenwich LifeSciences

Several institutional investors and hedge funds have recently made changes to their positions in GLSI. Rhumbline Advisers bought a new position in shares of Greenwich LifeSciences during the second quarter valued at $117,000. Barclays PLC grew its stake in shares of Greenwich LifeSciences by 323.3% in the third quarter. Barclays PLC now owns 8,560 shares of the company’s stock worth $123,000 after acquiring an additional 6,538 shares during the period. Garden State Investment Advisory Services LLC bought a new stake in shares of Greenwich LifeSciences in the third quarter worth approximately $253,000. Bank of New York Mellon Corp purchased a new position in shares of Greenwich LifeSciences during the second quarter valued at approximately $264,000. Finally, State Street Corp lifted its position in Greenwich LifeSciences by 4.4% during the third quarter. State Street Corp now owns 71,408 shares of the company’s stock valued at $1,026,000 after purchasing an additional 3,005 shares during the period. Institutional investors own 4.16% of the company’s stock.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.